menu
    • menu
    [{"orgOrder":0,"company":"Amgen Inc","sponsor":"Volastra Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Sovilnesib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Volastra Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Volastra Therapeutics"},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Polaris Partners","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Series A Financing","leadProduct":"Sovilnesib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Volastra Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"Volastra Therapeutics \/ Polaris Partners","highestDevelopmentStatusID":"6","companyTruncated":"Volastra Therapeutics \/ Polaris Partners"},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Volastra Therapeutics Announces First Patient Dosed in Phase Ib Clinical Trial of Sovilnesib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Sovilnesib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Volastra Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Volastra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Volastra Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Sovilnesib

    Menu

    Sovilnesib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Volastra Therapeutics

                            U.S.A arrow
                            IPEX Indonesia
                            Not Confirmed

                            Volastra Therapeutics

                            U.S.A arrow
                            IPEX Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sovilnesib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Volastra Therapeutics Announces First Patient Dosed in Phase Ib Clinical Trial of Sovilnesib

                            Details : AMG-650 (sovilnesib) is a KIF18A inhibitor, small molecule drug candidate, which is being evaluated for the treatment of patients with platinum-resistant or refractory high-grade serous ovarian cancer.

                            Brand Name : AMG-650

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 16, 2024

                            Lead Product(s) : Sovilnesib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Amgen Inc

                            U.S.A arrow
                            IPEX Indonesia
                            Not Confirmed

                            Amgen Inc

                            U.S.A arrow
                            IPEX Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sovilnesib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Volastra Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding ...

                            Details : Under the terms of the licensing agreement, Volastra receives an exclusive worldwide license (ex-China) to develop and commercialize AMG650 (sovilnesib), an oral, first-in-class small molecule inhibitor of KIF18A.

                            Brand Name : AMG650

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 07, 2023

                            Lead Product(s) : Sovilnesib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Volastra Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Volastra Therapeutics

                            U.S.A arrow
                            IPEX Indonesia
                            Not Confirmed

                            Volastra Therapeutics

                            U.S.A arrow
                            IPEX Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sovilnesib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Polaris Partners

                            Deal Size : $60.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding ...

                            Details : The Funding will support clinical development of Volastra’s portfolio of KIF18A inhibitors including, AMG650 (sovilnesib), an oral, first-in-class small molecule, as well as advancement of a robust pipeline of research programs targeting chromosomally ...

                            Brand Name : AMG650

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 07, 2023

                            Lead Product(s) : Sovilnesib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Polaris Partners

                            Deal Size : $60.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth